It has been revealed that there’s a compound that is able to trigger lower COVID-19 mortality risks. Check out the latest reports below:
Lowering COVID-19 mortality risks
A recent study revealed that COVID patients who were treated with hydroxychloroquine had a lower mortality rate compared to those who didn’t receive the treatment.
The study conducted in France showed that only 0.8 percent of the patients who received hydroxychloroquine and an antibiotic died, whereas 4.8 percent of patients who didn’t receive the drug combination died. The results indicate that hydroxychloroquine might be an effective treatment for COVID-19.
“This study represents the largest single-center study evaluating HCQ-AZ in the treatment of COVID-19,” Dr. Didier Raoult, with Aix-Marseille Universite in Marseille, and his co-authors wrote.
“Similarly, to other large observational studies, it concludes that HCQ would have saved lives.”
The journal New Microbes and New Infections recently published a paper that was initially released as a preprint earlier this year.
However, the authors withdrew it, stating that they had changed their “analytic strategies.” The study examined records of 30,423 COVID-19 patients who received treatment at the IHU Méditerranée Infection hospital in Marseille.
The research included all adults who tested positive for COVID-19 and received treatment either as an inpatient or outpatient between March 2, 2020, and December 31, 2021.
Unfortunately, treatment information was not available for 221 of the patients, so the study only included data from 30,202 individuals.
The study found that a majority of patients were prescribed hydroxychloroquine and azithromycin (AZ), which is an antibiotic, even though it was not FDA approved for the treatment of COVID-19.
Out of the total sample, 23,172 patients were given the drug combination, while 7,030 were not given any of these drugs.
The death rate was significantly lower in the group that received HCQ and AZ, with only 0.8 percent of patients dying, compared to 4.8 percent in the group that did not receive these drugs.
This survival benefit was seen in both inpatients and outpatients.